X

Trial Profile

Pivotal phase III trial of pimavanserin in patients with Parkinson's disease-related psychosis (ACP-103-021).

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 14 Apr 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimavanserin (Primary)
Indications Parkinson's disease; Psychotic disorders
Focus Registrational; Therapeutic Use

Most Recent Events

11 Apr 2013 ACADIA will no longer conduct this trial following an FDA announcement indicating data from the 020 trial, in conjunction with earlier phase trials, was sufficient to support regulatory filing activities.
11 Apr 2013 Status changed from planning to discontinued based on information reported in an ACADIA Pharmaceuticals media release.
29 Nov 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com